Rubius Therapeutics (NASDAQ:RUBY) released its quarterly earnings data on Tuesday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.04), Briefing.com reports. During the same period in the previous year, the business posted ($3.33) earnings per share.
NASDAQ:RUBY traded up $0.05 during mid-day trading on Tuesday, reaching $11.26. The stock had a trading volume of 5,710 shares, compared to its average volume of 188,084. The company has a 50 day moving average of $14.13. Rubius Therapeutics has a fifty-two week low of $10.47 and a fifty-two week high of $26.90. The company has a market cap of $897.70 million and a PE ratio of -4.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64.
In other Rubius Therapeutics news, Director Robert Langer sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $14.94, for a total transaction of $112,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher L. Carpenter sold 47,757 shares of the company’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total value of $669,553.14. The disclosure for this sale can be found here. Corporate insiders own 58.40% of the company’s stock.
RUBY has been the topic of a number of research reports. ValuEngine upgraded Rubius Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright initiated coverage on Rubius Therapeutics in a report on Wednesday, June 26th. They issued a “buy” rating and a $40.00 price objective on the stock. Zacks Investment Research upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 24th. Finally, Guggenheim initiated coverage on Rubius Therapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $31.00.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Read More: Preferred Stock
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.